J. Mccloskey

发表

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.

H. Kantarjian, W. Stock, N. Jain, 2020, Blood advances.

Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population

C. Howlett, Jessica Hedvat, J. Mccloskey, 2016, Journal of Thrombosis and Thrombolysis.

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

H. Kantarjian, J. Cortes, W. Stock, 2018, Clinical Cancer Research.

Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.

G. Rosti, J. Cortes, M. Deininger, 2021, Blood.

Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms

Wanlong Ma, M. Albitar, A. Goy, 2022, Frontiers in Oncology.

Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment.

B. Cheson, C. Broome, J. Mccloskey, 2013, Clinical advances in hematology & oncology : H&O.

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

N. Daver, M. Levis, J. Altman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Use of Clofarabine for Adults and Children with Leukemia

D. Reinhardt, N. Hijiya, S. Faderl, 2017 .

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

A. Goldberg, M. Tallman, E. Padron, 2019, Blood.

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

B. Leber, H. Deeg, H. Kantarjian, 2020, Blood.

Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia

S. Faderl, Jamie L. Koprivnikar, J. Mccloskey, 2017, OncoTargets and therapy.

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia

T. Cluzeau, T. Cooper, R. Lemoli, 2022, Cancers.

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.

A. Goldberg, M. Tallman, E. Padron, 2020, Blood advances.

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

N. Daver, M. Levis, J. Altman, 2021, Blood.

Sapacitabine in acute myelogenous leukemia

S. Faderl, Jamie L. Koprivnikar, J. Mccloskey, 2015 .

Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML.

H. Kantarjian, G. Garcia-Manero, R. Wells, 2020, Blood.

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

H. Deeg, G. Garcia-Manero, K. Yee, 2019, Blood.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Angela G. Fleischman, A. Salar, S. Verstovsek, 2023, The Lancet.

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

H. Döhner, S. Choe, H. Kantarjian, 2020, Blood.

A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR

S. Goldberg, S. Faderl, C. Howlett, 2015 .

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Steven D Green, Huyuan Yang, J. Scandura, 2022, Blood.

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

N. Daver, M. Levis, J. Altman, 2020 .

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

B. Leber, H. Deeg, H. Kantarjian, 2021, Blood.

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

H. Döhner, S. Choe, M. Tallman, 2018, Blood.

Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence (AI).

Wanlong Ma, M. Albitar, A. Pecora, 2022, The American journal of pathology.

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

H. Kantarjian, W. Stock, N. Jain, 2017 .

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

G. Rosti, J. Cortes, M. Deininger, 2020 .

CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial.

G. Rosti, J. Cortes, M. Deininger, 2022, Clinical lymphoma, myeloma & leukemia.

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).

G. Rosti, M. Deininger, C. Chuah, 2021 .

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study

P. Chevallier, X. Thomas, G. Rossi, 2022, Cancer medicine.

Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors

Wanlong Ma, M. Albitar, A. Pecora, 2023, Heliyon.

Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

B. Leber, G. Garcia-Manero, K. Yee, 2022, Blood.

AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study

N. Daver, M. Levis, J. Altman, 2021 .

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

B. Leber, H. Deeg, H. Kantarjian, 2021, Blood.

Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

G. Rosti, J. Cortes, M. Deininger, 2022, Blood.

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

S. Goldberg, S. Faderl, Jamie L. Koprivnikar, 2017 .

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

H. Kantarjian, E. Jabbour, I. Aldoss, 2023, Journal of Clinical Oncology.

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

G. Rosti, M. Deininger, C. Chuah, 2022, Blood.

Prevalence and determinants of oral and cervicogenital HPV infection: baseline analysis of the MHOC cohort study

M. Eisenberg, T. Carey, K. Murphy, 2022, medRxiv.